250 related articles for article (PubMed ID: 25102891)
1. Bordetella pertussis fimbriae (Fim): relevance for vaccines.
Gorringe AR; Vaughan TE
Expert Rev Vaccines; 2014 Oct; 13(10):1205-14. PubMed ID: 25102891
[TBL] [Abstract][Full Text] [Related]
2. Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3.
Debrie AS; Coutte L; Raze D; Mooi F; Alexander F; Gorringe A; Mielcarek N; Locht C
Vaccine; 2018 Mar; 36(11):1345-1352. PubMed ID: 29433898
[TBL] [Abstract][Full Text] [Related]
3. Antibody responses to Bordetella pertussis Fim2 or Fim3 following immunization with a whole-cell, two-component, or five-component acellular pertussis vaccine and following pertussis disease in children in Sweden in 1997 and 2007.
Hallander H; Advani A; Alexander F; Gustafsson L; Ljungman M; Pratt C; Hall I; Gorringe AR
Clin Vaccine Immunol; 2014 Feb; 21(2):165-73. PubMed ID: 24307240
[TBL] [Abstract][Full Text] [Related]
4. Bordetella pertussis isolates in Finland: serotype and fimbrial expression.
Heikkinen E; Xing DK; Olander RM; Hytönen J; Viljanen MK; Mertsola J; He Q
BMC Microbiol; 2008 Sep; 8():162. PubMed ID: 18816412
[TBL] [Abstract][Full Text] [Related]
5. Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five-component acellular pertussis vaccine or to pertussis disease.
Alexander F; Matheson M; Fry NK; Labram B; Gorringe AR
Clin Vaccine Immunol; 2012 Nov; 19(11):1776-83. PubMed ID: 22956654
[TBL] [Abstract][Full Text] [Related]
6. Bordetella pertussis isolates in Finland after acellular vaccination: serotype change and biofilm formation.
Niinikoski V; Barkoff AM; Mertsola J; He Q
Clin Microbiol Infect; 2024 May; 30(5):683.e1-683.e3. PubMed ID: 38310999
[TBL] [Abstract][Full Text] [Related]
7. Biological differences between FIM2 and FIM3 fimbriae of Bordetella pertussis: not just the serotype.
Matczak S; Bouchez V; Leroux P; Douché T; Collinet N; Landier A; Gianetto QG; Guillot S; Chamot-Rooke J; Hasan M; Matondo M; Brisse S; Toubiana J
Microbes Infect; 2023; 25(7):105152. PubMed ID: 37245862
[TBL] [Abstract][Full Text] [Related]
8. Increasing FIM2/3 antigen-content improves efficacy of Bordetella pertussis vaccines in mice in vivo without altering vaccine-induced human reactogenicity biomarkers in vitro.
Queenan AM; Dowling DJ; Cheng WK; Faé K; Fernandez J; Flynn PJ; Joshi S; Brightman SE; Ramirez J; Serroyen J; Wiertsema S; Fortanier A; van den Dobbelsteen G; Levy O; Poolman J
Vaccine; 2019 Jan; 37(1):80-89. PubMed ID: 30478007
[TBL] [Abstract][Full Text] [Related]
9. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
Barkoff AM; Guiso N; Guillot S; Xing D; Markey K; Berbers G; Mertsola J; He Q
J Immunol Methods; 2014 Jun; 408():142-8. PubMed ID: 24925807
[TBL] [Abstract][Full Text] [Related]
10. Should fimbriae be included in pertussis vaccines? Studies on ELISA IgG anti-Fim2/3 antibodies after vaccination and infection.
Hallander HO; Ljungman M; Jahnmatz M; Storsaeter J; Nilsson L; Gustafsson L
APMIS; 2009 Sep; 117(9):660-71. PubMed ID: 19703126
[TBL] [Abstract][Full Text] [Related]
11. A Novel Bvg-Repressed Promoter Causes
Chen Q; Lee G; Craig C; Ng V; Carlson PE; Hinton DM; Stibitz S
J Bacteriol; 2018 Oct; 200(20):. PubMed ID: 30061354
[TBL] [Abstract][Full Text] [Related]
12. Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines.
Meade BD; Lynn F; Reed GF; Mink CM; Romani TA; Deforest A; Deloria MA
Pediatrics; 1995 Sep; 96(3 Pt 2):595-600. PubMed ID: 7659484
[TBL] [Abstract][Full Text] [Related]
13. The length of poly(C) stretch in the Bordetella pertussis Pfim3 promoter determines the vag or vrg function of the fim3 gene.
Otsuka N; Guiso N; Bouchez V
Microbiology (Reading); 2017 Sep; 163(9):1364-1368. PubMed ID: 28809156
[TBL] [Abstract][Full Text] [Related]
14. Rapid and accurate typing of Bordetella pertussis targeting genes encoding acellular vaccine antigens using real time PCR and High Resolution Melt analysis.
Chan WF; Maharjan RP; Reeves PR; Sintchenko V; Gilbert GL; Lan R
J Microbiol Methods; 2009 Jun; 77(3):326-9. PubMed ID: 19341769
[TBL] [Abstract][Full Text] [Related]
15. Plasticity of fimbrial genotype and serotype within populations of Bordetella pertussis: analysis by paired flow cytometry and genome sequencing.
Vaughan TE; Pratt CB; Sealey K; Preston A; Fry NK; Gorringe AR
Microbiology (Reading); 2014 Sep; 160(Pt 9):2030-2044. PubMed ID: 25028460
[TBL] [Abstract][Full Text] [Related]
16. A Bordetella pertussis acellular vaccine candidate: antigenic characterization and antibody induction.
Dias WO; Horton DS; Takahashi CM; Raw I
Braz J Med Biol Res; 1994 Nov; 27(11):2607-11. PubMed ID: 7549983
[TBL] [Abstract][Full Text] [Related]
17. Detection of antibodies against fimbria type 3 (Fim3) is useful diagnostic assay for pertussis.
Oguchi K; Miyata A; Kazuyama Y; Noda A; Suzuki E; Watanabe M; Nakayama T
J Infect Chemother; 2015 Sep; 21(9):639-46. PubMed ID: 26134278
[TBL] [Abstract][Full Text] [Related]
18. Localization of antigenic domains on the major subunits of Bordetella pertussis serotype 2 and 3 fimbriae.
Pearce AM; Seabrook RN; Irons LI; Ashworth LA; Atkinson T; Robinson A
Microbiology (Reading); 1994 Jan; 140 ( Pt 1)():205-11. PubMed ID: 7512870
[TBL] [Abstract][Full Text] [Related]
19. Bordetella pertussis vaccine strains and circulating isolates in Serbia.
Dakic G; Kallonen T; Elomaa A; Pljesa T; Vignjevic-Krastavcevic M; He Q
Vaccine; 2010 Feb; 28(5):1188-92. PubMed ID: 19945417
[TBL] [Abstract][Full Text] [Related]
20. Pertactin-deficient
Barkoff AM; Mertsola J; Pierard D; Dalby T; Hoegh SV; Guillot S; Stefanelli P; van Gent M; Berbers G; Vestrheim D; Greve-Isdahl M; Wehlin L; Ljungman M; Fry NK; Markey K; He Q
Euro Surveill; 2019 Feb; 24(7):. PubMed ID: 30782265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
